![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Research will focus on using Marengo’s TriSTAR platform to reinvigorate and mobilize selective V beta T cells to boost anti-tumor activity in patients with difficult-to-treat cold tumors.
Lead Product(s): T Cell Engager
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: $1,200.0 million Upfront Cash: Undisclosed
Deal Type: Partnership June 07, 2024
Details:
STAR0602, is a fusion protein that binds to a specific region of TCR Vβ and delivers a unique activation signal on the same T cell, leading to a selective expansion of the targeted T cell subclones. STAR0602 is the first T cell activator generated by Marengo's STAR platform.
Lead Product(s): STAR0602
Therapeutic Area: Oncology Product Name: STAR0602
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2022
Details:
Marengo will lead the preclinical development efforts and will expense related costs until the submission of an Investigational New Drug (IND) application to the U.S. FDA. Ipsen will assume responsibilities for clinical development and commercialization of STAR0602.
Lead Product(s): STAR002
Therapeutic Area: Oncology Product Name: STAR002
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: $1,592.0 million Upfront Cash: $45.0 million
Deal Type: Partnership August 01, 2022
Details:
STAR0602, is an antibody fusion molecule that binds and activates a specific Vβ TCR variant T cell subset while also delivering additional signals to the same T cell to further re-program the T cell to enhance anti-tumor activity.
Lead Product(s): STAR0602
Therapeutic Area: Oncology Product Name: STAR0602
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2022
Details:
STAR0602, is an antibody fusion molecule that binds and activates a specific Vβ TCR variant T cell subset while also delivering additional signals to the same T cell (known as cis-targeting) to further reprogram the T cell, to enhance anti-tumor activity.
Lead Product(s): STAR0602
Therapeutic Area: Oncology Product Name: STAR0602
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Kings College London
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 08, 2021